Ocular Hypertension Completed Phase 4 Trials for Travoprost (DB00287)

Also known as: Intraocular pressure raised / Ocular Hypertension (OHT) / Hypertension Ocular / Hypertension, Ocular / Intraocular pressure high / Intraocular hypertension / Ocular Hypertension (OH) / Elevated intraoccular pressure / Intraocular pressure increased / IOP increased / Raised IOP / Ocular tension increased / Tension ocular increased / Pressure intraocular increased / Increased intraocular pressure

IndicationStatusPhase
DBCOND0074237 (Ocular Hypertension)Completed4
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00798759Examination of Ocular Surface Effects With Administration of Travatan Z and XALATANTreatment
NCT02097719Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular HypertensionTreatment
NCT00539526Evaluation of Hyperemia With the Use of Ocular Prostaglandin AnaloguesTreatment
NCT00471380A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular HypertensionTreatment
NCT00527592A Single Dose Comfort Comparison of Travatan Z in One Eye Versus Xalatan in the Opposite Eye in Patients With Primary Open-Angle Glaucoma or Ocular HypertensionTreatment
NCT00847483Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-Weeks, Masked Evaluator, Phase IV Multi-Center Study in the USTreatment
NCT00708422Effects of Travatan Z and Xalatan on Ocular Surface HealthTreatment
NCT01995136Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension GlaucomaTreatment
NCT01937312Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin AnalogueTreatment
NCT01937299Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z®Treatment
NCT01253902Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular HypertensionTreatment
NCT01263444Safety and Efficacy of Adding AZARGA® Adjunctive to Prostaglandin TherapyTreatment
NCT01464424Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)Treatment
NCT01493427Efficacy of Changing to TRAVATAN® From Prior TherapyTreatment
NCT01664039An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®Treatment
NCT0165575824-hour Control of Intraocular Pressure (IOP) in Ocular HypertensionTreatment
NCT01547598Safety and Efficacy of LUMIGAN® RC Versus DuoTrav® in Patients Who Require Further Intraocular Pressure (IOP) ReductionTreatment
NCT01881126An Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular HypertensionTreatment
NCT00061503Mechanism of Action of TRAVATAN 0.004% in Subjects With Glaucoma or Ocular HypertensionTreatment
NCT00440011Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%Treatment